Stockreport

Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION

Mesoblast Limited - American Depositary Shares  (MESO) 
US:NASDAQ Investor Relations: investorsmedia.mesoblast.com
PDF Working with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial awareness efforts  ~15,000 children are living with DMD in [Read more]